Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$12.34 USD
-0.07 (-0.56%)
Updated Jun 4, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Cidara Therapeutics, Inc. [CDTX]
Reports for Purchase
Showing records 61 - 80 ( 145 total )
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Ph 3 ReSPECT Study Now Open For Enrollment
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rezafungin and Cloudbreak Aiming to Join the War Against COVID-19
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; ReSTORE Finish Line Pushed Back Slightly
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Analyst Day Sheds Light on KOL and Commercial Thoughts
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Mundipharma Partnership Alleviates Financing Concerns; Upgrading to OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Rezafungin Continues to Impress, but Financing Risk Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2019 PacGrow Healthcare Conference: Day 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Topline STRIVE Part B Data Supports Ongoing Ph 3 ReSTORE
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL and reducing PT to $2; Financing Risk Significant
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.